RedHill Biopharma Ltd. Overview
Pro stress-test →RedHill Biopharma is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases, oncology, and medical countermeasures. The company is advancing a diversified pipeline addressing large market opportunities with government support for multiple programs.
Strategic Profile
Pro stress-test →RedHill's drugs are largely de-risked and are potentially of lower cost and faster to market than new chemical entities under development, with products based on several technology platforms addressing several disease targets for risk diversification. RedHill recently began a joint U.S. commercial launch of Talicia (H. pylori treatment) with Cumberland in February 2026.
Competitive Landscape
Pro stress-test →RedHill operates in fragmented specialty pharma markets. Primary competitors include major pharma companies in H. pylori treatment (AbbVie with legacy products), specialty infectious disease players (Cipla, others in travelers' diarrhea), and emerging biotech companies targeting GLP-1 side effects. RedHill's advantage lies in portfolio diversification and government-supported programs, though it faces competition from larger, better-capitalized companies.
Industry Context
RedHill Biopharma Ltd. operates in Specialty Biopharmaceuticals - Gastrointestinal and Infectious Diseases.
Key facts
Founded: 2009 · Headquarters: Tel Aviv, Israel